BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 11859853)

  • 1. Improved fibrinolysis after one year of treatment with enalapril in men and women with uncomplicated myocardial infarction.
    Boman KO; Jansson JH; Nyhlén KA; Nilsson TK
    Thromb Haemost; 2002 Feb; 87(2):311-6. PubMed ID: 11859853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of ACE inhibition on the fibrinolytic system in patients requiring coronary artery bypass grafting.
    Walter T; Szabo S; Kazmaier S; Suselbeck T; Borggrefe M; Hoffmeister HM
    Thorac Cardiovasc Surg; 2009 Sep; 57(6):368-71. PubMed ID: 19707983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of atenolol or losartan on fibrinolysis and von Willebrand factor in hypertensive patients with left ventricular hypertrophy.
    Boman K; Boman JH; Andersson J; Olofsson M; Dahlöf B
    Clin Appl Thromb Hemost; 2010 Apr; 16(2):146-52. PubMed ID: 19825910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Questioning a class effect: does ACE inhibitor tissue penetration influence the degree of fibrinolytic balance alteration following an acute myocardial infarction?
    Tsikouris JP; Suarez JA; Meyerrose GE; Ziska M; Fike D; Smith J
    J Clin Pharmacol; 2004 Feb; 44(2):150-7. PubMed ID: 14747423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leptin levels are not affected by enalapril treatment after an uncomplicated myocardial infarction, but associate strongly with changes in fibrinolytic variables in men.
    Eriksson MA; Söderberg S; Nilsson TK; Eriksson M; Boman K; Jansson JH
    Scand J Clin Lab Invest; 2020 Jul; 80(4):303-308. PubMed ID: 32125188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early initiation of low-dose atorvastatin treatment after an acute ST-elevated myocardial infarction, decreases inflammatory process and prevents endothelial injury and activation.
    Stefanadi E; Tousoulis D; Antoniades C; Katsi V; Bosinakou E; Vavuranakis E; Triantafyllou G; Marinou K; Tsioufis C; Papageorgiou N; Latsios G; Stefanadis C
    Int J Cardiol; 2009 Apr; 133(2):266-8. PubMed ID: 18187214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between serum angiotensin-converting enzyme activity and plasma plasminogen activator inhibitor activity in patients with recent myocardial infarction.
    Moriyama Y; Ogawa H; Oshima S; Arai H; Takazoe K; Shimomura H; Hirai N; Suefuji H; Soejima H; Nishiyama K; Misumi K; Yasue H
    Coron Artery Dis; 1998; 9(10):691-6. PubMed ID: 9894621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Magnesium therapy, fibrinolytic parameters and von Willebrand factor in acute myocardial infarction.
    Thögersen AM; Jansson JH; Wester PO
    Int J Cardiol; 1996 Sep; 56(1):53-9. PubMed ID: 8891805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The complex between tPA and PAI-1: risk factor for myocardial infarction as studied in the SHEEP project.
    Nordenhem A; Leander K; Hallqvist J; de Faire U; Sten-Linder M; Wiman B
    Thromb Res; 2005; 116(3):223-32. PubMed ID: 15935831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in plasma C-reactive protein and hemostatic factors prior to and after a first myocardial infarction with a median follow-up time of 8 years.
    Thøgersen AM; Nilsson TK; Weinehall L; Boman K; Eliasson M; Hallmans G; Jansson JH
    Blood Coagul Fibrinolysis; 2009 Jul; 20(5):340-6. PubMed ID: 19357504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study.
    Wiman B; Andersson T; Hallqvist J; Reuterwall C; Ahlbom A; deFaire U
    Arterioscler Thromb Vasc Biol; 2000 Aug; 20(8):2019-23. PubMed ID: 10938026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Fibrinolytic system in patients with myocardial infarction and other coronary disease risk factors].
    Moreno JA; Gálvez MM; Cornudella R; Angós JA; Romero MS; Gutiérrez M
    Sangre (Barc); 1994 Apr; 39(2):111-6. PubMed ID: 8059288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A dynamic comparative study concerning the effects of angiotensin-converting enzyme inhibitors and aldosterone receptor blockers on the fibrinolytic system.
    Usalan C; Buyukhatipoglu H
    Clin Appl Thromb Hemost; 2008 Apr; 14(2):203-9. PubMed ID: 18372278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. von Willebrand factor, soluble P-selectin, tissue plasminogen activator and plasminogen activator inhibitor in atherosclerosis.
    Blann AD; Dobrotova M; Kubisz P; McCollum CN
    Thromb Haemost; 1995 Aug; 74(2):626-30. PubMed ID: 8584997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of prolonged dalteparin treatment on coagulation, fibrinolysis and inflammation in unstable coronary artery disease.
    Oldgren J; Fellenius C; Boman K; Jansson JH; Nilsson TK; Wallentin L; Siegbahn A
    J Intern Med; 2005 Nov; 258(5):420-7. PubMed ID: 16238677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of Cilazapril on endothelial cell function and fibrinolysis system in the canine atrial fibrillation models].
    Li WM; Han W; Liang ZJ; Wu DL; Huang YL; Cui SJ; Li Y
    Zhonghua Xin Xue Guan Bing Za Zhi; 2005 May; 33(5):469-72. PubMed ID: 15932713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of carvedilol or metoprolol on PAI-1, tPA-mass concentration or Von Willebrand factor in chronic heart failure--a COMET substudy.
    Boman K; Jansson JH; Nilsson T; Swedberg K; Cleland JG; Poole-Wilson P
    Thromb Res; 2010 Feb; 125(2):e46-50. PubMed ID: 19762071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated tissue plasminogen activator in patients with screening-detected abdominal aortic aneurysm.
    Wanhainen A; Nilsson TK; Bergqvist D; Boman K; Björck M
    J Vasc Surg; 2007 Jun; 45(6):1109-13. PubMed ID: 17543671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enalapril related changes in the fibrinolytic system in survivors of myocardial infarction.
    Jansson JH; Boman K; Nilsson TK
    Eur J Clin Pharmacol; 1993; 44(5):485-8. PubMed ID: 8359188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin-converting enzyme inhibition alters the fibrinolytic response to cardiopulmonary bypass.
    Pretorius M; Murphey LJ; McFarlane JA; Vaughan DE; Brown NJ
    Circulation; 2003 Dec; 108(25):3079-83. PubMed ID: 14656921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.